FDA grants full ap­proval to Keytru­da in tu­mor-ag­nos­tic set­ting; Can­del paus­es tri­al en­roll­ment

In a first, Mer­ck has se­cured a full ap­proval for Keytru­da in a tu­mor ag­nos­tic set­ting — as a treat­ment for any un­re­sectable or metasta­t­ic sol­id …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.